# Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

> **NCT07095868** · PHASE1,PHASE2 · RECRUITING · sponsor: **Everest Medicines (Beijing) Co., Ltd.** · enrollment: 94 (estimated)

## Conditions studied

- Selected Types of Solid Tumor

## Interventions

- **BIOLOGICAL:** EVM14
- **COMBINATION_PRODUCT:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07095868
- **Lead sponsor:** Everest Medicines (Beijing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2029-11
- **Final completion:** 2031-11
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07095868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07095868, "Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07095868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*